| __timestamp | Novartis AG | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 91733000 |
| Thursday, January 1, 2015 | 14247000000 | 87644000 |
| Friday, January 1, 2016 | 14192000000 | 92365000 |
| Sunday, January 1, 2017 | 14997000000 | 85656000 |
| Monday, January 1, 2018 | 16471000000 | 88196000 |
| Tuesday, January 1, 2019 | 14369000000 | 89971000 |
| Wednesday, January 1, 2020 | 14197000000 | 93413000 |
| Friday, January 1, 2021 | 14886000000 | 91355000 |
| Saturday, January 1, 2022 | 14253000000 | 113676000 |
| Sunday, January 1, 2023 | 12489000000 | 198366000 |
| Monday, January 1, 2024 | 12566000000 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Novartis AG and Taro Pharmaceutical Industries Ltd. have showcased contrasting strategies in this domain. From 2014 to 2023, Novartis AG's SG&A expenses fluctuated, peaking in 2018, while Taro's expenses remained relatively stable, with a notable increase in 2023.
Novartis AG, a Swiss multinational, saw its SG&A costs decrease by approximately 17% from 2018 to 2023, indicating a strategic shift towards cost optimization. In contrast, Taro, an Israeli company, experienced a 140% rise in SG&A expenses in the same period, suggesting a potential expansion or increased operational costs.
This data highlights the diverse approaches these companies take in managing their operational expenses, reflecting broader trends in the pharmaceutical industry.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Revenue Showdown: Novartis AG vs Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends